1525TiP TORNADO: A randomized multicenter open-label phase II study evaluating retifanlimab in combination with neoadjuvant chemotherapy in patients with selected retroperitoneal sarcomas

Abstract

Despite optimal surgery, up to 40% of patients with retroperitoneal sarcomas (RPS) will develop locoregional and/or distant relapse. Peri-operative radiotherapy has failed to improve outcome of these patients (Bonvalot et al Lancet Oncol 2020). Innovative strategies are urgently needed in this setting. Recent studies have shown the positive impact on overall survival of neoadjuvant systemic therapy in high-risk soft-tissue sarcoma (STS) of the extremities or trunk wall (Issels et al Lancet Oncol 2010; Gronchi et al Lancet Oncol 2017).